Cited by 175SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesImmune responses and vaccinations

The DOI matches its Crossref record; 31 of the 39 references it cites were found in a registry or an index.

SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63

Open access

Woldemeskel, Bezawit A., Garliss, Caroline C., Blankson, Joel N.·2021·Journal of Clinical Investigation

Open this paper in CoChat — free account Open PDF

Abstract

Recent studies have shown T cell cross-recognition of SARS-CoV-2 and common cold coronavirus spike proteins. However, the effect of SARS-CoV-2 vaccines on T cell responses to common cold coronaviruses (CCCs) remains unknown. In this study, we analyzed CD4+ T cell responses to spike peptides from SARS-CoV-2 and 3 CCCs (HCoV-229E, HCoV-NL63, and HCoV-OC43) before and after study participants received Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) mRNA-based COVID-19 vaccines. Vaccine recipients showed broad T cell responses to the SARS-CoV-2 spike protein, and we identified 23 distinct targeted peptides in 9 participants, including 1 peptide that was targeted in 6 individuals. Only 4 of these 23 targeted peptides would potentially be affected by mutations in the UK (B.1.1.7) and South African (B.1.351) variants, and CD4+ T cells from vaccine recipients recognized the 2 variant spike proteins as effectively as they recognized the spike protein from the ancestral virus. Interestingly, we observed a 3-fold increase in the CD4+ T cell responses to HCoV-NL63 spike peptides after vaccination. Our results suggest that T cell responses elicited or enhanced by SARS-CoV-2 mRNA vaccines may be able to control SARS-CoV-2 variants and lead to cross-protection against some endemic coronaviruses.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci149335

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 2×
“Results and Discussion The Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) mRNA vaccines elicit strong T cell responses to SARS-CoV-2 (11, 12).”
Background
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
The Immune Epitope Database (IEDB): 2018 update
Vita, R., Mahajan, S., Overton, J. A., Dhanda, S. K., Martini, S. R., Cantrell, J. R., Wheeler, D. K., Sette, A., & Peters, B. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1006 · Cited by 2,194
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343

Flagged first, then by citations

Show all 39 references

8 of the 39 references couldn’t be matched to a known paper.

Sorted by citations

The T cell immune response against SARS-CoV-2
Moss, P. A. H. (2022) · Nature Immunology · doi:10.1038/s41590-021-01122-w · Cited by 1,243
Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination
Painter, M. M., Mathew, D., Goel, R. R., Apostolidis, S. A., Pattekar, A., Kuthuru, O., Baxter, A. E., Herati, R. S., Oldridge, D. A., Gouma, S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.001 · Cited by 499
Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
Sette, A., & Crotty, S. (2022) · Immunological Reviews · doi:10.1111/imr.13089 · Cited by 270
The germinal centre B cell response to SARS-CoV-2
Laidlaw, B. J., & Ellebedy, A. H. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00657-1 · Cited by 268
BNT162b2 vaccination induces durable SARS-CoV-2–specific T cells with a stem cell memory phenotype
Guerrera, G., Picozza, M., D’Orso, S., Placido, R., Pirronello, M., Verdiani, A., Termine, A., Fabrizio, C., Giannessi, F., Sambucci, M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl5344 · Cited by 230
T Cell Responses to SARS-CoV-2
Sette, A., Sidney, J., & Crotty, S. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-061120 · Cited by 191
COVID-19 Vaccination and Glomerulonephritis
Klomjit, N., Alexander, M. P., Fervenza, F. C., Zoghby, Z., Garg, A., Hogan, M. C., Nasr, S. H., Minshar, M. A., & Zand, L. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.09.008 · Cited by 182
Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy
Haque, A., & Pant, A. B. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102792 · Cited by 189
SARS-CoV-2-specific T cells in infection and vaccination
Bertoletti, A., Le Bert, N., Qui, M., & Tan, A. T. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00743-3 · Cited by 159
Adaptive Immune Responses and Immunity to SARS-CoV-2
Primorac, D., Vrdoljak, K., Brlek, P., Pavelić, E., Molnar, V., Matišić, V., Ivkošić, I. E., & Parčina, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848582 · Cited by 162
The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)
Woldemeskel, B. A., Karaba, A. H., Garliss, C. C., Beck, E. J., Wang, K., Laeyendecker, O. B., Cox, A. L., & Blankson, J. N. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab648 · Cited by 135
Self-citation
Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong
Peng, Q., Zhou, R., Wang, Y., Zhao, M., Liu, N., Li, S., Huang, H., Yang, D., Au, K., Wang, H., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103904 · Cited by 122
Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals
Tan, A. T., Lim, J. M. E., Bert, N. L., Kunasegaran, K., Chia, A., Qui, M., Tan, N., Chia, W. N., de Alwis, R., Ying, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152379 · Cited by 110
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy
Gadani, S. P., Reyes-Mantilla, M. I., Jank, L., Harris, S., Douglas, M., Smith, M. D., Calabresi, P. A., Mowry, E. M., Fitzgerald, K. C., & Bhargava, P. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103636 · Cited by 104
Comparison of Seroconversion in Children and Adults With Mild COVID-19
Toh, Z. Q., Anderson, J., Mazarakis, N., Neeland, M. R., Higgins, R. A., Rautenbacher, K., Dohle, K., Nguyen, J., Overmars, I., Donato, C. M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.1313 · Cited by 102
Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies
Ré, D., Seitz‐Polski, B., Brglez, V., Carlès, M., Graça, D., Benzaken, S., Liguori, S., Zahreddine, K., Delforge, M., Bailly‐Maitre, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28578-0 · Cited by 99
Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review
Pooley, N., Karim, S. S. A., Combadière, B., Ooi, E. E., Harris, R. C., Guerche‐Séblain, C. E., Kisomi, M., & Shaikh, N. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00753-2 · Cited by 95
Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8 + T-Cell Epitopes Identified in COVID-19 Convalescent Individuals
Redd, A. D., Nardin, A., Kared, H., Bloch, E. M., Abel, B., Pekosz, A. S., Laeyendecker, O. B., Fehlings, M., Quinn, T. C., & Tobian, A. A. R. (2022) · mBio · doi:10.1128/mbio.03617-21 · Cited by 93
mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status
Neidleman, J. A., Luo, X., McGregor, M. M., Xie, G., Murray, V., Greene, W. C., Lee, S. A., & Roan, N. R. (2021) · eLife · doi:10.7554/elife.72619 · Cited by 89
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort
Aldridge, R. W., Yavlinsky, A., Nguyen, V. G., Eyre, M. T., Shrotri, M., Navaratnam, A. M. D., Beale, S., Braithwaite, I., Byrne, T., Kovar, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32265-5 · Cited by 84
mRNA vaccines: The future of prevention of viral infections?
Rzymski, P., Szuster‐Ciesielska, A., Dzieciątkowski, T., Gwenzi, W., & Fal, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28572 · Cited by 75
Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies
Noori, M., Nejadghaderi, S. A., Arshi, S., Carson‐Chahhoud, K., Ansarin, K., Kolahi, A., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2277 · Cited by 64
Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory
Wragg, K. M., Lee, W. S., Koutsakos, M., Tan, H., Amarasena, T. H., Reynaldi, A., Gare, G., Konstandopoulos, P., Field, K. R., Esterbauer, R., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01175-5 · Cited by 68
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
Assawakosri, S., Kanokudom, S., Suntronwong, N., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Duangchinda, T., Chantima, W., Pakchotanon, P., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac092 · Cited by 60
Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine
Kramer, K. J., Wilfong, E. M., Voss, K., Barone, S. M., Shiakolas, A. R., Raju, N., Roe, C. E., Suryadevara, N., Walker, L. M., Wall, S. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31142-5 · Cited by 58
BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality
Jung, M. K., Jeong, S. D., Noh, J. Y., Kim, D.-U., Jung, S., Song, J. Y., Jeong, H. W., Park, S., & Shin, E. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01123-x · Cited by 54
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article
Barrière, J., Carlès, M., Audigier-Valette, C., Ré, D., Adjtoutah, Z., Seitz‐Polski, B., Gounant, V., Descamps, D., & Zalcman, G. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.011 · Cited by 56
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Rocha, V. P. C., Soares, M. B. P., Berglund, P., Duthie, M. S., Reed, S. G., et al. (2021) · Vaccines · doi:10.3390/vaccines9111345 · Cited by 55
How long does covid-19 immunity last?
Baraniuk, C. (2021) · BMJ · doi:10.1136/bmj.n1605 · Cited by 45
Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2
Salleh, M. Z., Norazmi, M. N., & Deris, Z. Z. (2022) · PeerJ · doi:10.7717/peerj.13083 · Cited by 45
Human CD4+ T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential
Verhagen, J., van der Meijden, E. D., Lang, V., Kremer, A. E., Völkl, S., Mackensen, A., Aigner, M., & Kremer, A. N. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13627 · Cited by 40
Evaluation of the QuantiFERON SARS-CoV-2 interferon-ɣ release assay in mRNA-1273 vaccinated health care workers
Krüttgen, A., Klingel, H., Haase, G., Haefner, H., Imöhl, M., & Kleines, M. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114295 · Cited by 41
Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease
Malipiero, G., Moratto, A., Infantino, M. G., D’Agaro, P., Piscianz, E., Manfredi, M., Grossi, V., Benvenuti, E., Bulgaresi, M., Benucci, M., et al. (2021) · Immunologic Research · doi:10.1007/s12026-021-09226-z · Cited by 42
Peculiarities of the T Cell Immune Response in COVID-19
Kudlay, D. A., Кофиади, И. А., & Khaitov, M. R. (2022) · Vaccines · doi:10.3390/vaccines10020242 · Cited by 43
The past, current and future epidemiological dynamic of SARS-CoV-2
Balloux, F., Tan, C. C. S., Swadling, L., Richard, D., Jenner, C., Maini, M. K., & van Dorp, L. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac003 · Cited by 41
Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2
Liu, D., Chen, C., Chen, D., Zhu, A., Li, F., Zhuang, Z., Mok, C. K. P., Dai, J., Li, X., Jin, Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2202820120 · Cited by 43
Accuracy and real life performance of a novel interferon-γ release assay for the detection of SARS-CoV2 specific T cell response
Huzly, D., Panning, M., Smely, F., Enders, M., Komp, J., Falcone, V., & Steinmann, D. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105098 · Cited by 38
Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity
Lin, J., Law, R., Korosec, C. S., Zhou, C. Y., Koh, W. H., Ghaemi, M. S., Samaan, P., Ooi, H. K., Matveev, V., Yue, F., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00509-22 · Cited by 38
TNF-α+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies
van der Ploeg, K., Kirosingh, A. S., Mori, D. A., Chakraborty, S., Hu, Z., Sievers, B. L., Jacobson, K. B., Bonilla, H. F., Parsonnet, J., Andrews, J. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100640 · Cited by 36
Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S
Barbeau, D. J., Martin, J. M., Carney, E., Dougherty, E., Doyle, J., Dermody, T. S., Hoberman, A., Williams, J. V., Michaels, M. G., Alcorn, J. F., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00504-x · Cited by 37
Cellular Immunity—The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination
Primorac, D., Brlek, P., Matišić, V., Molnar, V., Vrdoljak, K., Zadro, R., & Parčina, M. (2022) · Vaccines · doi:10.3390/vaccines10030442 · Cited by 35
Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID ‐19 vaccination
Riise, J., Meyer, S., Blaas, I., Chopra, A., Tran, T. T., Delić-Šarac, M., Hestdalen, M. L., Brodin, E. E., Rustad, E. H., Dai, K., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18149 · Cited by 32
Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals
Johansson, A. M., Malhotra, U., Kim, Y. G., Gomez, R., Krist, M. P., Wald, A., Koelle, D. M., & Kwok, W. W. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010203 · Cited by 35
Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination
Stankov, M. V., Cossmann, A., Bonifacius, A., Dopfer‐Jablonka, A., Ramos, G. M., Gödecke, N., Scharff, A. Z., Happle, C., Boeck, A.-L., Tran, A. T., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab555 · Cited by 31
SARS -CoV-2 T-cell immunity to variants of concern following vaccinationPreprint
Gallagher, K., Leick, M. B., Larson, R. C., Berger, T. R., Katsis, K., Yam, J. Y., Brini, G., Grauwet, K., MGH COVID-19 Collection & Processing Team, & Maus, M. V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.03.442455 · Cited by 32
CD4+ T cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses
Woldemeskel, B. A., Dykema, A. G., Garliss, C. C., Cherfils, S., Smith, K. N., & Blankson, J. N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156083 · Cited by 29
Self-citation
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
Räuber, S. J., Korsen, M., Huntemann, N., Rolfes, L., Müntefering, T., Dobelmann, V., Hermann, A. M., Kölsche, T., Lipinski, K. V. W., Schroeter, C. B., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328197 · Cited by 30
Seasonal respiratory virus circulation was diminished during the COVID‐19 pandemic
Heiskanen, A., Galipeau, Y., Little, J., Mortimer, L., Ramotar, K., Langlois, M., & Cooper, C. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13065 · Cited by 30
A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation
Binayke, A., Zaheer, A., Vishwakarma, S., Singh, S., Sharma, P., Chandwaskar, R., Gosain, M., Raghavan, S., Murugesan, D. R., Kshetrapal, P., et al. (2024) · npj Vaccines · doi:10.1038/s41541-023-00794-9 · Cited by 28
Sex, Age, and Ethnic Background Shape Adaptive Immune Responses Induced by the SARS-CoV-2 mRNA Vaccine
Bai, J., Chiba, A., Murayama, G., Kuga, T., Tamura, N., & Miyake, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.786586 · Cited by 27
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19
Aurisicchio, L., Brambilla, N., Cazzaniga, M. E., Bonfanti, P., Milleri, S., Ascierto, P. A., Capici, S., Vitalini, C., Girolami, F., Giacovelli, G., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.12.017 · Cited by 29
Comparing the B and T cell-mediated immune responses in patients with type 2 diabetes receiving mRNA or inactivated COVID-19 vaccines
Lee, C., Gray, V., Teo, J. M. N., Tam, A. R., Fong, C. H.-Y., Lui, D. T. W., Pang, P., Chan, K. H., Hung, I. F., Tan, K. C. B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018393 · Cited by 26
Variants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody/vaccine sensitivity
Prüβ, B. M. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2702065 · Cited by 26
SARS-CoV-2 immunity and vaccine strategies in people with HIV
Mullender, C., da Costa, K., Alrubayyi, A., Pett, S. L., & Peppa, D. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac005 · Cited by 23
Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine
Saresella, M., Piancone, F., Marventano, I., Hernis, A., Trabattoni, D., Invernizzi, M., Rosa, F. L., & Clerici, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947320 · Cited by 24
Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2
Peng, Q., Zhou, R., Liu, N., Wang, H., Xu, H., Zhao, M., Yang, D., Au, K., Huang, H., Liu, L., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00924-8 · Cited by 26
Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases
Cheung, M. W., Dayam, R. M., Shapiro, J. R., Law, J. C., Chao, G. Y. C., Pereira, D. A. S., Goetgebuer, R., Croitoru, D. O., Stempak, J. M., Acheampong, L., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300190 · Cited by 24
mRNA Vaccine-Elicited Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells Persist at 6 Months and Recognize the Delta Variant
Woldemeskel, B. A., Garliss, C. C., & Blankson, J. N. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab915 · Cited by 25
Self-citation
Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies
D’Amelio, R., Asero, R., Cassatella, M. A., Laganà, B., Lunardi, C., Migliorini, P., Nisini, R., Parronchi, P., Quinti, I., Racanelli, V., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091163 · Cited by 22
Rapid induction of antigen-specific CD4 + T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccinationPreprint
Painter, M. M., Mathew, D., Goel, R. R., Apostolidis, S. A., Pattekar, A., Kuthuru, O., Baxter, A. E., Herati, R. S., Oldridge, D. A., Gouma, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.21.440862 · Cited by 23
SARS-CoV-2–specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge
Woldemeskel, B. A., Garliss, C. C., Aytenfisu, T. Y., Johnston, T. S., Beck, E. J., Dykema, A. G., Frumento, N., Wright, D. A., Yang, A. H., Damanakis, A. I., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159474 · Cited by 22
Self-citation
SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection
Dykema, A. G., Zhang, B., Woldemeskel, B. A., Garliss, C. C., Rashid, R., Westlake, T., Zhang, L., Zhang, J., Cheung, L. S., Caushi, J. X., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104048 · Cited by 23
Self-citation
Immunogenicity of COVID ‐19 vaccines in chronic liver disease patients and liver transplant recipients: A systematic review and meta‐analysis
Luo, D., Chen, X., Du, J., Mei, B., Wang, A., Kuang, F. L., Fang, C., Gan, Y., Peng, F., Yang, X., et al. (2022) · Liver International · doi:10.1111/liv.15403 · Cited by 22
Keeping T cell memories in mind
Mix, M. R., & Harty, J. T. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.10.001 · Cited by 21
Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study
Ravussin, A., Robertson, A. H., Wolf, A., Blix, K., Kjønstad, I. F., Solum, G., Feiring, B., Strand, B. H., Lund‐Johansen, F., Munthe, L. A., et al. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00055-7 · Cited by 22
Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272
Bozzi, G., Lombardi, A., Ludovisi, S., Muscatello, A., Manganaro, L., Cattaneo, D., Gori, A., & Bandera, A. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.10.021 · Cited by 21
mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic
Xu, Z., & Fisher, D. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155728 · Cited by 21
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
Sahly, H. M. E., Baden, L. R., Essink, B. J., Montefiori, D. C., McDermont, A., Rupp, R. E., Lewis, M., Swaminathan, S., Griffin, C., Fragoso, V. G., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac188 · Cited by 21
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies
Rouhani, S. J., Yu, J., Olson, D. J., Zha, Y., Pezeshk, A., Cabanov, A., Pyzer, A. R., Trujillo, J., Derman, B. A., O’Donnell, P. H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004766 · Cited by 21
Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus
Tortellini, E., Ngangue, Y. C. F., Dominelli, F., Guardiani, M., Falvino, C., Mengoni, F., Carraro, A., Marocco, R., Pasculli, P., Mastroianni, C. M., et al. (2023) · Viruses · doi:10.3390/v15091844 · Cited by 24
Does immunosuppressive property of non-steroidal anti-inflammatory drugs (NSAIDs) reduce COVID-19 vaccine-induced systemic side effects?
Kazama, I., & Senzaki, M. (2021) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2021.01094 · Cited by 20
Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?
Gussarow, D., Bonifacius, A., Cossmann, A., Stankov, M. V., Mausberg, P., Tischer‐Zimmermann, S., Gödecke, N., Kalinke, U., Behrens, G. M. N., Blasczyk, R., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.770381 · Cited by 18
Omicron BA.2 breakthrough infection elicits CD8 + T cell responses recognizing the spike of later Omicron subvariants
Kim, S.-H., Kim, J., Jung, S., Noh, J. Y., Kim, J. N., Park, H., Song, Y. G., Peck, K. R., Park, S., Park, M., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.ade6132 · Cited by 19
Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2
Tarabini, R. F., Rigo, M., Fonseca, A. F., Rubin, F. P., Belle, R. L., Kavraki, L. E., Ferreto, T. C., Antunes, D. A., & de Souza, A. P. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.812176 · Cited by 16
SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels
Mostafa, H. H., Luo, C. H., Morris, C. P., Li, M., Swanson, N. J., Amadi, A., Gallagher, N., & Pekosz, A. S. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105151 · Cited by 18
A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2
Jin, X., Liu, X. K., & Shen, C. (2022) · Virus Research · doi:10.1016/j.virusres.2022.199024 · Cited by 18
Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2
Becerra‐Artiles, A., Nanaware, P. P., Muneeruddin, K., Weaver, G. C., Shaffer, S. A., Calvo‐Calle, J. M., & Stern, L. J. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011032 · Cited by 18
Multipolymer microsphere delivery of SARS-CoV-2 antigens
Shahjin, F., Patel, M., Machhi, J., Cohen, J. D., Nayan, M. U., Yeapuri, P., Zhang, C., Waight, E. M., Hasan, M., Abdelmoaty, M. M., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.12.043 · Cited by 15
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size
Duncan, M. C., Omondi, F. H., Kinloch, N. N., Lapointe, H. R., Speckmaier, S., Moran-Garcia, N., Lawson, T., DeMarco, M. L., Simons, J. E., Holmes, D. T., et al. (2024) · AIDS · doi:10.1097/qad.0000000000003841 · Cited by 16
Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients
Černá, K., Ďuricová, D., Hindos, M., Hrebackova, J. H., Lukáš, M., Machková, N., Hrubá, V., Mitrová, K., Kubíčková, K., Kastylova, K., et al. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac048 · Cited by 16
Quality of T-Cell Response to SARS-CoV-2 mRNA Vaccine in ART-Treated PLWH
Tortellini, E., Zingaropoli, M. A., Mancarella, G., Marocco, R., Carraro, A., Jamhour, M., Barbato, C., Guardiani, M., Dominelli, F., Pasculli, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314988 · Cited by 16
Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2
Ameratunga, R., Woon, S.-T., Steele, R., Lehnert, K., Leung, E. Y., & Brooks, A. E. S. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2074403 · Cited by 16
Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory
Bai, J., Chiba, A., Murayama, G., Kuga, T., Yahagi, Y., Tabe, Y., Tamura, N., & Miyake, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-24938-4 · Cited by 17
Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant
Peled, Y., Afek, A. B., Kreiss, Y., Rahav, G., Nemet, I., Kliker, L., Indenbaum, V., Ram, E., Lavee, J., Segev, A., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.05.014 · Cited by 15
The Influence of Cross-Reactive T Cells in COVID-19
Eggenhuizen, P. J., & Ooi, J. D. (2024) · Biomedicines · doi:10.3390/biomedicines12030564 · Cited by 14
Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2
Monzon‐Posadas, W. O., Zorn, J., Peters, K., Baum, M., Proksch, H., Schlüter, C. B., Menting, T., Pušnik, J., & Streeck, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1066123 · Cited by 13
A unique cytotoxic CD4 + T cell‐signature defines critical COVID‐19
Baird, S., Ashley, C. L., Marsh‐Wakefield, F., Alca, S., Ashhurst, T. M., Ferguson, A. L., Lukeman, H., Counoupas, C., Post, J. J., Koneçny, P., et al. (2023) · Clinical & Translational Immunology · doi:10.1002/cti2.1463 · Cited by 12
A modular mRNA vaccine platform encoding antigen-presenting capsid virus-like particles enhances the immunogenicity of the malaria antigen Pfs25
Fougeroux, C. E., Hagen, S. H., Goksøyr, L., Aves, K.-L., Okholm, A. K., Morin, C., Lokras, A. G., Baghel, S. S., Foged, C., van de Vegte‐Bolmer, M., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01889-1 · Cited by 15
T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine
Sophonmanee, R., Ongarj, J., Seeyankem, B., Seepathomnarong, P., Intapiboon, P., Surasombatpattana, S., Uppanisakorn, S., Sangsupawanich, P., Chusri, S., & Pinpathomrat, N. (2022) · Vaccines · doi:10.3390/vaccines10091494 · Cited by 13
Bivalent COVID-19 Vaccines: Can the Original Antigenic Sin Be Forgiven?
Blankson, J. N. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad073 · Cited by 13
Self-citation
DNA origami vaccine (DoriVac) nanoparticles improve both humoral and cellular immune responses to infectious diseasesPreprint
Zeng, Y. C., Young, O. J., Xiong, Q., Si, L., Ku, M., Bernier, S. G., Dembele, H., Isinelli, G., Gilboa, T., Swank, Z., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.29.573647 · Cited by 13
Cell Squeeze: driving more effective CD8 T-cell activation through cytosolic antigen delivery
Park, J. C., Bernstein, H., Loughhead, S. M., Zwirtes, R. F., Jennings, J. K., Nicolini, V., Klein, C., Deak, L. C., Umaña, P., Trumpfheller, C., et al. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100091 · Cited by 12
Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection
Park, H.-S., Shapiro, J. R., Sitaras, I., Woldemeskel, B. A., Garliss, C. C., Dziedzic, A., Sachithanandham, J., Jedlicka, A., Caputo, C. A., Rousseau, K. E., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155944 · Cited by 10
Self-citation
SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern
Ma, Q., Li, M., Ma, L., Zhang, C., Zhang, H., Zhong, H., Wen, J., Wang, Y., Yan, Z., Xiong, W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1195299 · Cited by 11
Progress and Challenges Toward Generation and Maintenance of Long-Lived Memory T Lymphocyte Responses During COVID-19
Kumar, S., Saxena, S. K., Maurya, V. K., & Tripathi, A. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.804808 · Cited by 12
An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19
Soleimanian, S., Alyasin, S. S., Sepahi, N., Ghahramani, Z., Kanannejad, Z., Yaghobi, R., & Karimi, M. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884879 · Cited by 11
Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology
Khanolkar, A. (2021) · Cells · doi:10.3390/cells11010067 · Cited by 12
DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases
Zeng, Y. C., Young, O. J., Xiong, Q., Si, L., Ku, M., Bernier, S. G., Dembele, H., Isinelli, G., Gilboa, T., Swank, Z., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01614-w · Cited by 29
Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4+ T cell clonotypes
Sop, J., Traut, C. C., Dykema, A. G., Hunt, J. H., Beckey, T. P., Basseth, C. R., Antar, A. A. R., Laeyendecker, O. B., Smith, K. N., & Blankson, J. N. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101442 · Cited by 10
Self-citation
Large inter-individual variability of cellular and humoral immunological responses to mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in health care workers
Krüttgen, A., Haase, G., Haefner, H., Imöhl, M., & Kleines, M. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.1.96 · Cited by 11

Authors: Woldemeskel, B. A., Garliss, C. C., & Blankson, J. N.
Corresponding author: Blankson, Joel N.
ORCID: Blankson, Joel N.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2021-05-17
Volume: 131
Issue: 10
ISSN: 0021-9738 (ISSN-L)
1558-8238
DOI: 10.1172/jci149335
PMC: PMC8121504
OpenAlex: W3141087105
Cited by: 175
References: 39
Citations by year: 2026: 7 · 2025: 9 · 2024: 16 · 2023: 24 · 2022: 72 · 2021: 47
FWCI: 12.58
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: NIH (R01AI120024)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Keywords: COVID-19 mRNA vaccine, BNT162b2, mRNA-1273, CD4+ T cell responses, common cold coronaviruses, HCoV-NL63, HCoV-229E, HCoV-OC43, SARS-CoV-2 variants, Alpha variant, Beta variant, cross-protection, vaccine-induced immunity
MeSH terms: SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adult, Cross Reactions, Female, Humans, Male, Middle Aged, RNA, Messenger, CD4-Positive T-Lymphocytes, Coronavirus 229E, Human, Coronavirus OC43, Human, Coronavirus NL63, Human, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks